About FSHD Canada Foundation
Funded Research

Muscle targeted immunosuppression as an FSHD therapeutic

Investigator: Andreia Marcelino Nunes, PhD; University of Nevada, Reno School of Medicine FSHD is caused by aberrant increased expression of the DUX4 gene in skeletal myocytes, which initiates a pathogenic…

Read More

Generation of porcine large animal models for FSHD therapeutic development and preclinical testing

Investigators: Peter L. Jones Lab; University of Nevada, Reno School of Medicine The primary therapeutic target in all forms of FSHD is DUX4-fl mRNA and DUX4-FL protein, and animal models…

Read More

Motor Outcomes to Validate Evaluations in FSHD

Investigators: Jeffrey Statland, PI (University of Kansas Medical Center); and Rabi Tawil, Co-PI (University of Rochester Medical Center) The primary goal of this proposal is to hasten therapeutic development for…

Read More

Facio Therapies

Facio Therapies, established in 2014, is a Netherlands-based company with a single focus – to overcome FSHD by developing a causal therapy that restores the natural repression of muscle-toxic DUX4.…

Read More

Mouse Model to Validate Drugs Targeting DUX4 Enhancer/Promoter Activity

Investigator: Yosuke Hiramuki, Ph.D. at the University of Nevada, Reno We created a mouse model to validate the effect of drugs targeting DUX4 gene expression in a whole living organism.…

Read More

Testing the efficacy of CRISPRi in FSHD2

Investigators: Takako Jones, PhD and Charis L. Himeda, PhD; University of Nevada, Reno School of Medicine The goal of this proposal is to test the utility of our CRISPR inhibition…

Read More
https://twitter.com/#!/FSHDCanada/ http://www.facebook.com/pages/FSHD-Canada/331378503625267 /contact Suite 201, 1100 1st St. SE Calgary, Alberta T2G 1B1 403.470.0141 neil.camarta@fshd.ca